[D] Viewbix Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 shows Sangamo Therapeutics (SGMO) CFO Prathyusha Duraibabu surrendered 31,866 common shares on 22-Jul-2025 at $0.4798 per share. The “F” code indicates the shares were withheld by the company to cover taxes triggered by a restricted-stock-unit (RSU) vesting event, not an open-market sale.

After the transaction, the executive still owns 746,279 shares directly. The footnotes detail remaining unvested equity: 178,125 RSU shares from the Jan-2024 grant, 15,030 from Feb-2023, and 120,000 from Feb-2025, all vesting through 2028 if continuous service is maintained. The filing is routine and does not signal a change in outlook or insider sentiment.

Positive

• High remaining ownership: CFO still holds 746,279 shares, indicating continued alignment with shareholders.

Negative

• Net insider disposition: 31,866 shares were surrendered, though for tax purposes and immaterial in value.

Insights

Senior Equity Analyst

TL;DR: Routine tax-withholding share surrender; negligible financial impact.

The CFO’s 31,866-share disposition is compulsory for tax withholding on RSU vesting, worth roughly $15k—immaterial to SGMO’s float. Post-transaction ownership of 746k shares demonstrates continued insider alignment. No purchase or discretionary sale occurred, so the filing is operationally neutral. Investors can view it as routine equity-compensation housekeeping rather than a signal about future fundamentals.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number:			3235-0076
Estimated average burden
hours per response:			4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

None

Entity Type

0000797542

Virtual Crypto Technologies, Inc.

Emerald Medical Applications Corp.

ZAXIS INTERNATIONAL INC

X	Corporation
	Limited Partnership
	Limited Liability Company
	General Partnership
	Business Trust
	Other (Specify)

Name of Issuer

Viewbix Inc.

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

X	Over Five Years Ago
	Within Last Five Years (Specify Year)
	Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Viewbix Inc.
Street Address 1		Street Address 2
3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
TEL AVIV	ISRAEL	6971068	855-879-8439

3. Related Persons

Last Name	First Name	Middle Name
Hadad	Amihay
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer

Last Name	First Name	Middle Name
Marom	Shahar
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name	First Name	Middle Name
Yoresh	Eliyahu
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Weiss	Amitay
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Carmel	Liron
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Dayan	Alon
Street Address 1	Street Address 2
c/o Viewbix Inc.	3 HANEHOSHET ST, BUILDING B, 7TH FLOOR
City	State/Province/Country	ZIP/PostalCode
Tel Aviv	ISRAEL	6971068

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance

Investing

Investment Banking

Pooled Investment Fund

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

	Health Care
	Biotechnology
	Health Insurance
	Hospitals & Physicians
	Pharmaceuticals
	Other Health Care
	Manufacturing
	Real Estate
	Commercial
	Construction
	REITS & Finance
	Residential
	Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

X Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		Rule 504(b)(1) (not (i), (ii) or (iii))
		Rule 504 (b)(1)(i)
		Rule 504 (b)(1)(ii)
		Rule 504 (b)(1)(iii)
	X	Rule 506(b)
		Rule 506(c)
		Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)

Section 3(c)(2) Section 3(c)(10)

Section 3(c)(3) Section 3(c)(11)

Section 3(c)(4) Section 3(c)(12)

Section 3(c)(5) Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2025-07-11				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
X	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient	Recipient CRD Number None
Aegis Capital Corp.	000015007
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None
Aegis Capital Corp.	000015007
Street Address 1	Street Address 2
1345 Avenue of the Americas, 27th Floor
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10105
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	X Foreign/non-US
CALIFORNIA CONNECTICUT DELAWARE FLORIDA NEVADA NEW JERSEY NEW YORK TEXAS PUERTO RICO

13. Offering and Sales Amounts

Total Offering Amount	$8,900,000	USD	or Indefinite
Total Amount Sold	$8,900,000	USD
Total Remaining to be Sold	$0	USD	or Indefinite

Clarification of Response (if Necessary):

Aggregate gross proceeds were approximately $4.5 million, before deducting fees and other offering expenses payable by the Company. If the Warrants are exercised in cash in full this would result in an additional $4.4 million of gross proceeds.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

12

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$314,999	USD	Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

• Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Viewbix Inc.	/s/ Amihay Hadad	Amihay Hadad	Chief Executive Officer	2025-07-24

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

FAQ

Why did SGMO's CFO dispose of 31,866 shares?

Shares were automatically withheld by the company on 22-Jul-2025 to satisfy tax obligations from RSU vesting.

How many SGMO shares does Prathyusha Duraibabu own after the Form 4 transaction?

The CFO directly owns 746,279 shares following the surrender.

Was the transaction an open-market sale?

No. The filing uses code “F,” signifying a tax-withholding surrender, not a discretionary market trade.

What price was used for the tax-withholding shares?

The issuer’s closing price of $0.4798 on 22-Jul-2025 determined the withholding value.

What future vesting remains for the CFO's RSUs?

178,125 shares from a Jan-2024 grant, 15,030 from Feb-2023, and 120,000 from Feb-2025 will vest through 2028, subject to continued service.